SPECTAMINE
LOE Approachingiofetamine hydrochloride i-123
NDAINJECTIONINJECTABLE
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTAMINE is an injectable radiopharmaceutical containing iofetamine hydrochloride labeled with Iodine-123, used as a diagnostic imaging agent for brain perfusion studies. It is a small-molecule radioimaging compound that localizes in the brain to assess cerebral blood flow and detect abnormalities in regional perfusion.
LOE Approaching
This mature diagnostic agent faces declining market dynamics typical of legacy radiopharmaceuticals; commercial teams are likely small and focused on retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SPECTAMINE offers limited career growth potential due to advanced lifecycle stage and declining market dynamics. Roles focus on operational efficiency, compliance, and market management rather than innovation or expansion.
Product Manager (Diagnostics)Sales Operations Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.